148 related articles for article (PubMed ID: 38156346)
1.
Leopold C; Poblete S; Vogler S
J Law Med Ethics; 2023; 51(S1):76-91. PubMed ID: 38156346
[TBL] [Abstract][Full Text] [Related]
2. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
3. [Policies encouraging price competition in the generic drug market: Lessons from the European experience].
Puig-Junoy J
Gac Sanit; 2010; 24(3):193-9. PubMed ID: 20189690
[TBL] [Abstract][Full Text] [Related]
4. A comparison of generic drug prices in seven European countries: a methodological analysis.
Wouters OJ; Kanavos PG
BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
[TBL] [Abstract][Full Text] [Related]
5. Generic medicine pricing in Europe: current issues and future perspective.
Simoens S
J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
[TBL] [Abstract][Full Text] [Related]
6. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
7. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America.
Moye-Holz D; Vogler S
Appl Health Econ Health Policy; 2022 Jan; 20(1):67-77. PubMed ID: 34228312
[TBL] [Abstract][Full Text] [Related]
10. Value-Based Pricing in Latin America: How Far Away Are We?
Mejía A; Gilardino R; Kristensen FB; Garrison LP;
Value Health Reg Issues; 2018 Dec; 17():219-223. PubMed ID: 30528780
[TBL] [Abstract][Full Text] [Related]
11. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
12. Convergence of decision rules for value-based pricing of new innovative drugs.
Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
[TBL] [Abstract][Full Text] [Related]
13. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
14. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
15. [Alternatives for adopting policies centered on access to medicines].
Tobar F; Drake I; Martich E
Rev Panam Salud Publica; 2012 Dec; 32(6):457-63. PubMed ID: 23370190
[TBL] [Abstract][Full Text] [Related]
16. IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES.
Pichon-Riviere A; Garay OU; Augustovski F; Vallejos C; Huayanay L; Bueno Mdel P; Rodriguez A; de Andrade CJ; Buendía JA; Drummond M
Int J Technol Assess Health Care; 2015 Jan; 31(1-2):2-11. PubMed ID: 25989703
[TBL] [Abstract][Full Text] [Related]
17. The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review.
Preckler V; Espín J
Value Health; 2022 Apr; 25(4):666-675. PubMed ID: 35227598
[TBL] [Abstract][Full Text] [Related]
18. Optimal price regulations in international pharmaceutical markets with generic competition.
Geng D; Saggi K
J Health Econ; 2020 May; 71():102315. PubMed ID: 32273046
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Medicine Prices in New Zealand and 16 European Countries.
Vogler S; Kilpatrick K; Babar ZU
Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
[TBL] [Abstract][Full Text] [Related]
20. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
